John G. Saia Net Worth

The estimated Net Worth of John G. Saia is at least $1.38 Million dollars as of 1 September 2024. Mr Saia owns over 263 units of Guardant Health Inc stock worth over $728,840 and over the last 7 years he sold GH stock worth over $0. In addition, he makes $651,287 as Sr. VP and Gen. Counsel & Corp. Sec. at Guardant Health Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr Saia GH stock SEC Form 4 insiders trading

Mr has made over 16 trades of the Guardant Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 263 units of GH stock worth $6,541 on 1 September 2024.

The largest trade he's ever made was exercising 7,569 units of Guardant Health Inc stock on 15 April 2024 worth over $188,241. On average, Mr trades about 940 units every 24 days since 2018. As of 1 September 2024 he still owns at least 29,306 units of Guardant Health Inc stock.

You can see the complete history of Mr Saia stock trades at the bottom of the page.

Mr. John G. Saia biography

John G. Saia is the Sr. VP, Gen. Counsel & Corp. Sec. at Guardant Health Inc.

What is the salary of Mr Saia?

As the Sr. VP and Gen. Counsel & Corp. Sec. of Guardant Health Inc, the total compensation of Mr Saia at Guardant Health Inc is $651,287. There are 4 executives at Guardant Health Inc getting paid more, with Michael Wiley having the highest compensation of $2,216,070.

How old is Mr Saia?

Mr Saia is 48, he's been the Sr. VP and Gen. Counsel & Corp. Sec. of Guardant Health Inc since . There are 7 older and 8 younger executives at Guardant Health Inc. The oldest executive at Guardant Health Inc is Stanley Meresman, 73, who is the Independent Director.

What's Mr Saia's mailing address?

John's mailing address filed with the SEC is 3100, Hanover Street, Palo Alto, Santa Clara County, California, 94306, United States.

Insiders trading at Guardant Health Inc

Over the last 6 years, insiders at Guardant Health Inc have traded over $2,653,630,540 worth of Guardant Health Inc stock and bought 2,438,210 units worth $45,173,576 . The most active insiders traders include Bluebird (Cayman) Ltd Softb..., Bluebird (Cayman) Ltd Svf E..., and Helmy Eltoukhy. On average, Guardant Health Inc executives and independent directors trade stock every 6 days with the average trade being worth of $2,415,822. The most recent stock trade was executed by Kumud Kalia on 9 September 2024, trading 6,545 units of GH stock currently worth $162,774.

What does Guardant Health Inc do?

we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.

Complete history of Mr Saia stock trades at Acelrx Pharmaceuticals Inc and Guardant Health Inc

Guardant Health Inc executives and stock owners

Guardant Health Inc executives and other stock owners filed with the SEC include:

• Michael Wiley,
  Chief Legal Officer
• Derek Bertocci,
  Chief Financial Officer
• Helmy Eltoukhy,
  Chief Executive Officer, Director
• AmirAli Talasaz,
  Chairman of the Board, President, Chief Operating Officer
• John G. Saia,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Michael J. Wiley,
  Head of Corp. Affairs
• Dr. Richard B. Lanman,
  Advisor
• Bahija Jallal,
  Independent Director
• Ian Clark,
  Lead Independent Director
• Stanley Meresman,
  Independent Director
• Samir Kaul,
  Independent Director
• Dr. AmirAli Talasaz Ph.D.,
  Co-CEO & Director
• Dr. Helmy Eltoukhy Ph.D.,
  Co-Founder, Co-CEO & Chairman
• Lynn Lewis,
  IR Contact Officer
• Vijaya Gadde,
  Director
• Kumud Kalia,
  Chief Information Officer
• Dr. Richard B. Lanman M.D.,
  Advisor
• Steven Collora,
  VP of Sales
• Daniel Simon,
  Sr. VP of Biopharma Bus. Devel.
• Andy Ament,
  Sr. VP of Operations
• Mark Jacobstein,
  Chief User Engagement Officer
• Amelia Merrill,
  VP of People
• Michael Bell,
  Chief Financial Officer
• Richard B. Lanman,
  Chief Medical Officer
• Terilyn J. Monroe,
  Chief People Officer
• Musa Tariq,
  Director
• Craig Eagle,
  Chief Medical Officer
• Meghan V. Joyce,
  Director
• Group Capital Ltd Softbank ...,
  
• Us (Ttgp), Ltd.Sc U.S. Vent...,
  
• Vision Fund (Aiv M1) L.P.Sb...,
  
• Beta Pte. Ltd.Temasek Life ...,
  
• Advisors Llc Orbimed,
  10% owner
• Ultimate General Partner Se...,
  
• Ventures Iv, L.P.Khosla Ven...,
  
• Ultimate General Partner X,...,
  
• Bluebird (Cayman) Ltd Softb...,
  
• Dipchand Nishar,
  Director
• Aaref Hilaly,
  Director
• John G. Saia,
  Chief Legal Officer
• Bluebird (Cayman) Ltd Svf E...,
  
• Chris Freeman,
  Chief Commercial Officer
• Myrtle S Potter,
  Director
• Steve E. Krognes,
  Director
• Michael Brian Bell,
  Chief Financial Officer
• Amelia Merrill,
  SVP, People
• Medina Manuel Hidalgo,
  Director
• Darya Chudova,
  Chief Technology Officer
• Ines Dahne Steuber,
  Chief Operating Officer